logo-loader
viewCytoDyn Inc.

Cytodyn has raised over 190 million dollars as they look to commercialize lead drug

Cytodyn Inc. (OTCQB:CYDY) President and CEO Nader Pourhassan sat down with Christine Corrado from Proactive Investors New York at the ThinkEquity Conference.

Pourhassan addressed the company's recent share price fluctuation, and spoke about his presentation to investors at ThinkEquity.

Quick facts: CytoDyn Inc.

Price: 2.665 USD

OTCMKTS:CYDY
Market: OTCQB
Market Cap: $1.15 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn Get US FDA approval to move to FastTrack to Phase 2...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to discuss the company getting U.S. FDA  clearance to start a Phase 2 trial with leronlimab to treat COVID-19 patients with mild to moderate indications.  Pourhassan telling Proactive why they have been...

6 hours, 55 minutes ago

2 min read